ESM1 overexpression is closely associated with drug resistance to chemotherapy in breast cancer (BRCA) [13] and has certain impact on the clinical outcome of advanced gastric cancer after chemotherapy [14, 15], indicating that ESM1 is of potential clinical value in cancer patients. This evidence concerns the gene ESM1 and cancer.